Madison, Wis. – One of the speakers at last month’s World Stem Cell Summit in Madison wasn’t a scientist, a patient advocate, or a university administrator. She was an investor – an encouraging sign that human embryonic stem-cell research has entered a new and transformative phase.
Linda Powers of Toucan Capital, a Maryland-based investment firm, is like other venture capitalists in at least one major way – she invests to make money. But Powers is different from most other venture capitalists in at least one respect – she thinks she can make money by investing in stem cell companies.